Relationship between markers of endothelial dysfunction and inflammation and subclinical atherosclerosis in HIV-infected male patients below 55 years of age

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 23, Issue 3, 2014, Pages 49-52

  Pirs, Mateja ^a   Jug, Borut ^b   Eržen, Barbara ^b   Šabović, Mišo ^b   Karner, Primož ^b   Poljak, Mario ^a   Tomažič, Janez ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Endothelial dysfunction; HIV Infection; HsCRP; PAI 1; Subclinical atherosclerosis; VCAM 1

Indexed keywords

C REACTIVE PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; THROMBOSIS; BLOOD; CROSS-SECTIONAL STUDY; HIV INFECTIONS; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SLOVENIA; VASCULAR ENDOTHELIUM;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; SLOVENIA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84907261051     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.15570/actaapa.2014.12     Document Type: Article

References (37)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525-33.
2. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008;118:e20-8.
3. Delaney JA, Scherzer R, Biggs ML, Shliplak MG, Polak JF, Currier JS, et al. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS. 2010;24:2201-9.
4. Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 2013;27:381-9.
5. Fichtenbaum CJ. Inflammatory markers associated with coronary heart disease in persons with HIV infection. Curr Infect Dis Rep. 2010;13:94-101.
6. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-94.
7. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-25.
8. Rönsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS ONE. 2013;8:e65182.
9. López M, San Román J, Estrada V, Vispo E, Blanco F, Soriano V. Endothelial dysfunction in HIV infection - the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. AIDS Rev. 2012;14:223-30.
10. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocr Metab. 2001;86:939-43.
11. Pirš M, Erzen B, Sabovic M, Karner P, Vidmar L, Poljak M, et al. Early atherosclerosis in HIV-infected patients below the age of 55 years: Slovenian national study. Wien Klin Wochenschr. 2014;126:263-9.
12. Erzen B, Sabovic M, Sebestjen M, Poredos P. Endothelial dysfunction, intimamedia thickness, ankle-brachial pressure index, and pulse pressure in young post-myocardial infarction patients with various expressions of classical risk factors. Heart Vessels. 2007;22:215-22.
13. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
14. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-406.
15. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22.
16. Hsue PY. Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection. Circulation. 2004;109:316-9.
17. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23:75-80.
18. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-701.
19. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5:498-503.
20. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis. 2004;4:213-22.
21. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185:456-62.
22. Papasavvas E, Azzoni L, Pistilli M, Hancock A, Reynolds G, Gallo C, et al. Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS. 2008;22:1153-61.
23. Noursadeghi M, Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. International Journal of STD & AIDS. 2005;16:438-41.
24. Desvarieux M, Boccara F, Meynard J-L, Bastard J-P, Mallat Z, Charbit B, et al. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy. AIDS. 2013;27:2603-14.
25. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010;201:285-92.
26. Lebech A-M, Kristoffersen US, Wiinberg N, Kofoed K, Andersen O, Hesse B, et al. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging. 2008;35:2049-58.
27. Falcão MDCB de A, Zírpoli JC, Albuquerque VM de, Markman Filho B, Araújo NAM de, Falcão CA, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol. 2012;99:9718.
28. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-73.
29. De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, et al. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis. 2013;13:414.
30. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. Thorne C, editor. PLoS ONE. 2012;7:e44454.
31. Calza L, Pocaterra D, Pavoni M, Colangeli V, Manfredi R, Verucchi G, et al. Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV negative healthy controls. J Acquir Immune Defic Syndr. 2009;50:430-2.
32. Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS. 2009;23:589-96.
33. Melendez MM, Mcnurlan MA, Mynarcik DC, Khan S, Gelato MC. Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis. 2008;46:775-80.
34. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 2009;10:79-87.
35. Guzmán-Fulgencio M, Medrano J, Rallón N, Echeverria-Urabayen A, Benito JM, Restrepo C, et al. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect. 2011;63:382-90.
36. Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:441-9.
37. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198-210.